European Commission

Developer of a diagnostic tool designed to scan the immune system through simple, non-invasive clinical tests to broadly detect diseases at early stages. The company's tool provides a holistic, better view of the immune system to analyze how it responds to disease and interprets clinically useful and actionable information through computational analysis and AI (Artificial Intelligence) algorithms, it helps decode the immune system in high resolution to inform therapy and develop diagnostics through the convergence of immune cell sequencing and artificial intelligence, helping patients streamline disease detection and diagnosis.

AEInnova is a company incorporated in late 2014 with a vocation clearly oriented to research, innovation, and development of new products related to alternative energies. In particular, its main objective is the development of technologies for the production of electrical energy through the recovery of waste heat (thermoelectrical energy harvesting).

INDRESMAT is an international chemical startup based in Barcelona (Spain) & Geleen (The Netherlands) which mission is to become a game-changer in energy-efficiency in the construction market. Aiming a large scale implementation of high performance & sustainable materials towards Nearly-Zero Energy Buildings, INDRESMAT has unique know-how in bio-Polyurethane Chemistry. Integrated by a multidisciplinary team, our company is developing new disruptive projects that will contribute to reducing fossil CO2 emissions and ultimately fighting Climate Change.

AEInnova is a company incorporated in late 2014 with a vocation clearly oriented to research, innovation, and development of new products related to alternative energies. In particular, its main objective is the development of technologies for the production of electrical energy through the recovery of waste heat (thermoelectrical energy harvesting).

AEInnova is a company incorporated in late 2014 with a vocation clearly oriented to research, innovation, and development of new products related to alternative energies. In particular, its main objective is the development of technologies for the production of electrical energy through the recovery of waste heat (thermoelectrical energy harvesting).

Peptomyc S.L., founded in December 2014 and based in Barcelona, Spain, focuses on developing innovative cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. The company's approach is grounded in extensive scientific research, particularly the work on Omomyc, recognized as a leading Myc inhibitor. With global cancer incidence exceeding 14 million cases annually and projected to rise significantly, Peptomyc aims to address the limitations of conventional therapies, which often fail due to resistance. By targeting the Myc oncoprotein, which plays a critical role in cancer cell survival and is deregulated in many cancers, Peptomyc seeks to offer a promising therapeutic option where none currently exist. The company is particularly focused on developing treatments for lung, breast, and brain tumors, thereby enhancing the potential for improved patient survival outcomes.